StemCyte International, Ltd. (TPEX:4178)

Market Cap	4.71B
Revenue (ttm)	398.60M
Net Income (ttm)	-189.78M
Shares Out	192.21M
EPS (ttm)	-0.97
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	143,716
Average Volume	290,562
Open	25.20
Previous Close	25.20
Day's Range	24.20 - 25.20
52-Week Range	23.15 - 55.70
Beta	n/a
RSI	43.43
Earnings Date	Nov 14, 2025

About StemCyte International

StemCyte International, Ltd. operates cord blood cell banks in the United States and Taiwan. It supplies cord blood to medical centers for transplantation in the treatment of blood system diseases; and provides cord blood supply, mononuclear cell supply, and immune cell supply services. The company also develops cord blood to treat COVID-19 syndrome and acute ischemic stroke; and CB201, an immune cell drug. In addition, it offers cord blood storage, immune cell storage, and cord blood cell bank transplant cell services. The company was founded ...

• Industry: Miscellaneous Health And Allied Services, Not Elsewhere Classified
• Founded: 2013
• Country: Cayman Islands
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4178

Financial Performance

In 2024, StemCyte International's revenue was 382.69 million, an increase of 5.49% compared to the previous year's 362.78 million. Losses were -205.66 million, -35.68% less than in 2023.